

Registration, Students and Bursaries

Registration is open, and discounted rates are offered to RSC and SCI student members. The RSC and SCI are also offering some student bursaries. Registration fees include:

- gratis coach transport between Verona city centre and the Evotec campus at the start and end of each day
- dinner on Wednesday evening at the Ristorante Trisapori (formerly Scaligero)
- vineyard visit and dinner on Thursday evening at Rocca Sveva.

Standard registration fees, for payment by 5th September:

£600 Member of the RSC or SCI

£800 Non-member

£250 Student member, unemployed member, retired member

£350 Student non-member, unemployed non-member, retired non-member

Venue, Travel and Accommodation

Venue: Evotec Campus Levi-Montalcini, Verona, Italy

Travel: Detailed travel information may be found on the website.

Accommodation: Verona Booking is offering a hotel booking service.

Sponsors

We are grateful to Evotec for their generous support of this event. Additional sponsors would be welcomed.



Organising Committee

Daniele Andreotti, Evotec, IT
Adrian Hall (co-chairman), UCB, BE
Duncan Hay (treasurer), Vertex, UK
Caroline Low (co-chairman),
Isomorphic Laboratories, UK
Nigel Swain, Sosei Heptares, UK




Secretariat Contact

For further information, please contact the event secretariat: Maggi Churchouse, maggi.churchouse@rscbmcs.org

Website: <https://www.rscbmcs.org>

Also www.rsc.org/bmcs and www.soci.org/events

Final announcement



8th RSC / SCI Symposium on GPCRs in Medicinal Chemistry

Wednesday-Friday, 5th-7th October 2022

Evotec Campus Levi-Montalcini
Verona, Italy

Organised by:
RSC Biological and Medicinal Chemistry Sector and
SCI Fine Chemicals Group



Synopsis

The key role of G protein-coupled receptors (GPCRs) in human disease underpins their importance to modern medicine. We are pleased to be holding this 8th meeting in the series on GPCR drug discovery, which will combine cutting edge medicinal chemistry with innovative structural biology and novel drug design approaches.

Features of the Meeting

- Case studies in GPCR drug discovery and development
- Structural biology advances and impact on drug design
- Showcasing multiple modalities and drug discovery approaches to modulating GPCRs

Also: poster session - trade exhibition opportunities - two evening dinners and vineyard visit - accommodation agency booking service.

Programme

Wednesday, 5th October

- 08.30 Registration and refreshments
09.20 *Event welcome* - Karen Lackey, Evotec, US
09.40 *Site welcome* - Ciriaco Maraschiello, Evotec, IT
09.45 *Opening remarks* - Co-chair of the Organising Committee
09.50 *Structure-guided GPCR drug discovery* - **Keynote:** Bryan Roth, University of North Carolina Chapel Hill Medical School, US
10.40 *Discovery of PF-07081532: a small molecule GLP-1 receptor agonist suitable for once-daily oral administration* - David Griffith, Pfizer, US
11.20 Refreshments, exhibition and posters
11.50 *The resolution revolution: GPCR structure-based drug design in 20:20 vision (in 2022)* - James Errey, Evotec, UK
12.20 *Discovery of AZD5462, an oral agonist of the Relaxin family peptide receptor 1 (RXFP1) for the treatment of cardiorenal disease* - Kenneth Granberg, AstraZeneca, SE
12.50 Lunch, exhibition and posters
14.00 *Discovery of the clinical candidate ACT-777991, a potent CXCR3 antagonist with therapeutic potential in autoimmune diseases* - Eva Caroff, Idorsia, CH
14.30 *AlphaFold applied to GPCRs* - Miles Congreve and Caroline Low, Isomorphic Labs, UK
15.00 Refreshments, exhibition and posters
15.30 *Discovery of potent and selective S1P2 receptor antagonists for treatment of idiopathic pulmonary fibrosis* - Bertrand Heckmann, Galapagos, FR
16.00 *Targeting chemokine receptor CCR2 - from insurmountable antagonists to affinity-based probes* - Laura Heitman, University of Leiden, NL
16.30 Flash oral poster presentations (two-minute slots)
17.00 Poster session and drinks reception, followed by dinner in Verona city centre

Thursday, 6th October

- 09.30 *Biased signaling atlas and community guidelines* - **Keynote:** David Gloriam (virtual), University of Copenhagen, DK

- 10.20 *Discovery of MK-4710: a potent, selective, and bioavailable M4 positive allosteric modulator* - Michael Lo, MSD, US
10.50 Refreshments, exhibition and posters
11.20 *The discovery of CFTX-1554 as an inhibitor of the angiotensin II type 2 receptor, a clinically validated target for the treatment of neuropathic pain* - Ann De Blicke, Confo Therapeutics, BE
11.50 *Structure-based drug discovery across the medicinal chemical GPCRome* - Chris de Graaf, Sosei Heptares, UK
12.20 Lunch, exhibition, posters and Evotec site tours
13.30 Novel paradigms of allostery and bias at Class A GPCRs - **Keynote:** Celine Valant, Monash University, AU
14.20 *Impact of GPCR structure-based drug discovery on identification and optimisation of allosteric modulators that bind at the receptor-membrane interface* - Anna Cooper, Sosei Heptares, UK
14.50 Refreshments, exhibition and posters
15.20 *GPCR-based drug design with fragment molecular orbital method* - Alexander Heifetz, Evotec, UK
15.50 *Achieving fine control of GPCR function via learning and simulation of 3D structure* - **Keynote:** Ron Dror (virtual), Stanford University, US
16.40 Close, followed by vineyard visit and evening dinner

Friday, 7th October

- 09.30 *Tools for studying purine-activated and related orphan G protein-coupled receptors* - **Keynote:** Christa Müller, University of Bonn, DE
10.20 *Identification of H4R antagonist HTL0032547 as a potential therapy for atopic dermatitis* - Charlotte Fieldhouse, Sosei Heptares, UK
10.50 Refreshments, exhibition and posters
11.20 Poster prize-giving
11.25 *Discovery of VU6028418: a highly selective and orally bioavailable M4 muscarinic acetylcholine receptor antagonist* - Aaron Bender, Vanderbilt University, US
11.55 *Discovery of Pecavaptan: a novel dual acting vasopressin V1a/V2 receptor antagonist for the treatment of worsening chronic heart failure* - Carsten Schmeck, Bayer, DE
12.25 Lunch, exhibition and posters
13.20 *Selection of a clinical candidate profile based on GPCR signalling pathways: discovery of FPR2 agonist BMS-986331* - Nick Wurtz, Bristol-Myers Squibb, US
13:50 *Salipro DirectMX® enables discovery of novel therapeutics against GPCRs* - Robin Löving, Salipro, SE
14.25 Closing remarks - Co-chair of the Organising Committee
14:30 Close, and travel to transport hubs



Website: <https://www.rscbmcs.org>
Also www.rsc.org/bmcs and www.soci.org/events